Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Seres Theraptc (MCRB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 169,722
  • Shares Outstanding, K 41,095
  • Annual Sales, $ 28,270 K
  • Annual Income, $ -98,940 K
  • 60-Month Beta 1.80
  • Price/Sales 6.27
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.42
  • Number of Estimates 4
  • High Estimate -0.40
  • Low Estimate -0.49
  • Prior Year -0.68
  • Growth Rate Est. (year over year) +38.24%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.04 +2.23%
on 05/16/19
7.39 -44.11%
on 04/26/19
-2.71 (-39.62%)
since 04/17/19
3-Month
4.04 +2.23%
on 05/16/19
8.39 -50.77%
on 03/11/19
-1.98 (-32.41%)
since 02/15/19
52-Week
4.04 +2.23%
on 05/16/19
9.75 -57.64%
on 06/22/18
-4.22 (-50.54%)
since 05/17/18

Most Recent Stories

More News
Seres Therapeutics (MCRB) Reports Q1 Loss, Lags Revenue Estimates

Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -27.91% and -15.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

MCRB : 4.13 (-4.18%)
Seres Therapeutics: 1Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Seres Therapeutics Inc. (MCRB) on Thursday reported a loss of $24.3 million in its first quarter.

MCRB : 4.13 (-4.18%)
Seres Therapeutics Reports First Quarter Financial Results and Provides Clinical Pipeline Progress Update

--- SER-287 Fast Track designation obtained for active mild-to-moderate ulcerative colitis; Phase 2b study enrollment expected to be completed by mid-2020 and top-line data expected in Q3 2020 -

MCRB : 4.13 (-4.18%)
Seres Therapeutics, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 2, 2019 / Seres Therapeutics, Inc. (NASDAQ: ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 2, 2019 at 8:30 AM Eastern...

MCRB : 4.13 (-4.18%)
Seres Therapeutics to Host First Quarter 2019 Financial Results and Operational Progress Conference Call and Webcast on May 2, 2019

Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that management will host a conference call and live audio webcast on May 2, 2019 at 8:30 a.m. ET to discuss first quarter 2019...

MCRB : 4.13 (-4.18%)
Consolidated Research: 2019 Summary Expectations for Wyndham Hotels & Resorts, Apellis Pharmaceuticals, Transcat, Emerald Expositions Events, Capitala Finance, and Seres Therapeutics -- Fundamental Analysis, Key Performance Indications

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Wyndham Hotels & Resorts Inc. (NYSE:WH),...

WH : 55.39 (-0.91%)
MCRB : 4.13 (-4.18%)
TRNS : 24.30 (-0.21%)
CPTA : 8.97 (+0.56%)
APLS : 18.00 (-2.86%)
EEX : 12.69 (-0.78%)
Seres Therapeutics Presents New Preclinical Data Supporting the Development of SER-401 for Immuno-Oncology at the 2019 American Association for Cancer Research Annual Meeting

Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that new preclinical data supporting the development of microbiome therapeutics for immuno-oncology(poster title "Leveraging...

MCRB : 4.13 (-4.18%)
Seres Therapeutics (MCRB) in Focus: Stock Moves 6.7% Higher

Seres Therapeutics (MCRB) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

ADXS : 3.12 (+3.31%)
MCRB : 4.13 (-4.18%)
Seres Therapeutics Announces Microbiome Immuno-Oncology Focused Collaboration with AstraZeneca

--- Seres to receive $20 million and financial support for research activities -

MCRB : 4.13 (-4.18%)
Seres Therapeutics Reports Fourth Quarter and Full Year Financial Results and Provides Operational Updates

--- Initiated SER-401 Phase 1b study in metastatic melanoma -

MCRB : 4.13 (-4.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators mostly agree with the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade MCRB with:

Business Summary

Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.

See More

Key Turning Points

2nd Resistance Point 4.44
1st Resistance Point 4.29
Last Price 4.13
1st Support Level 4.02
2nd Support Level 3.90

See More

52-Week High 9.75
Fibonacci 61.8% 7.57
Fibonacci 50% 6.89
Fibonacci 38.2% 6.22
Last Price 4.13
52-Week Low 4.04

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar